kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
7,940
JPY
+495
(+6.65%)
Apr 28, 3:30 pm JST
49.87
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
7,870
Apr 28, 11:42 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.85
Yield
1.66%
Margin Trading Ratio
5.77
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
7,580 JPY 47.56 USD
Previous Close Apr 27
7,445 JPY 46.70 USD
High Apr 28, 12:39 pm
7,948 JPY 49.96 USD
Low Apr 28, 9:00 am
7,570 JPY 47.50 USD
Volume
5,707,500
Trading Value
0.04T JPY 0.28B USD
VWAP
7827.2 JPY 49.16 USD
Minimum Trading Value
794,000 JPY 4,987 USD
Market Cap
13.33T JPY 0.08T USD
Number of Trades
16,179
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
7,213
1-Year High Aug 8, 2025
42,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 54,200 817,900 15.09
Apr 17, 2026 46,100 898,700 19.49
Apr 10, 2026 64,300 742,900 11.55
Apr 3, 2026 55,000 754,700 13.72
Mar 27, 2026 52,100 726,500 13.94
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.